Strep A Vaccine Industry Forum: Catalyzing Industry Investment In Strep A Vaccine R&D
- SAVAC Industry Forum Report_2024.4.1.pdf Download
SAVAC 2.0 immunoassay workshop in Abu Dhabi on 3Nov 2023
- SAVAC 2.0 workshop for
immunoassay_3Nov2023.pdf Download
List of publications from SAVAC 1.0
SAVAC Protocols in OFID
- All articles Link
- Harmonizing Surveillance Methodologies for
Group A Streptococcal Diseases Link
- Standardization of Epidemiological
Surveillance of Group A Streptococcal Pharyngitis Link
- Standardization of Epidemiological
Surveillance of Group A Streptococcal Impetigo Link
- Standardization of Epidemiological
Surveillance of Group A Streptococcal Cellulitis Link
- Standardization of Epidemiological
Surveillance of Invasive Group A Streptococcal Infections
Link
- Standardization of Epidemiological
Surveillance of Acute Rheumatic Fever Link
- Standardization of Epidemiological
Surveillance of Rheumatic Heart Disease Link
- Standardization of Epidemiological
Surveillance of Acute Poststreptococcal Glomerulonephritis
Link
Data Purpose Matrix
SAVAC NPJ Vaccines health economics
papers
- Modeling the potential health impact of
prospective Strep A vaccines Link
- The potential global cost-effectiveness of
prospective Strep A vaccines and associated implementation
efforts Link
- Optimal global spending for group A
Streptococcus vaccine research and development Link
- Global economic burden per episode for
multiple diseases caused by group A Streptococcus Link
- A Strep A vaccine global demand and return
on investment forecast to inform industry research and
development prioritization Link
NPJ Vaccine pipeline
- The Streptococcus pyogenes vaccine
landscape Link
Safety paper
- Safety of Streptococcus pyogenes Vaccines:
Anticipating and Overcoming Challenges for Clinical Trials and
Post-Marketing Monitoring Link
Immune correlates paper
- Correlates of immunity to Group A
Streptococcus: a pathway to vaccine development Link
WHO expert review of Group A Streptococcus vaccines:
Hybrid Consultation by IVIR-AC and PDVAC, London, UK, 30
September 2022
- who-expert-review-of-gas-vx-exec-summary-pdvac-and-ivirac-final.pdf
Download
SAVAC 2nd Stakeholders meeting Report 06JUNE2022
- SAVAC 2nd Stakeholders meeting Report
06JUNE2022.pdf Download
Presentation slides at the second SAVAC Stakeholders
Meeting, 06 June 2022
- 1. A strategic approach to understand strep
A disease burden_Jonathan Carapetis.pdf Download
- 2. Immunologic protection and
correlates_Shiranee Sriskandan.pdf Download
- 3. Strep A Vaccine Safety Considerations
and Guidance during Development_Edwin Asturias.pdf Download
- 4. Potential impact of prospective strep A
vaccines on the global burden of disease_model based
analysis_Kaja Abbas.pdf Download
- 5. Global economic burden for Strep A
infections and cost effectiveness analysis for a hypothetical
Strep A vaccine_Jung Seok Lee.pdf Download
- 6. The full health economic social benefits
of vaccination_conceptual framework and application to Strep A
vaccines_Dan Cadarette.pdf Download
- 7. The Effect of a Prospective Vaccine
Against Group A Streptococcus on Global Antibiotic Consumption
for Sore Throat_Jeff Cannon.pdf Download
- 8. Global health and economic benefits
_Maddalena Ferranna.pdf Download
- 9. Business Case for Industry Investment in
Strep A Vaccine R&D_Don Walkinshaw.pdf Download
- 10. Optimal Global Spending for Group A
Streptococcus Vaccine Research and Development_Dan
Tortorice.pdf Download
SAVAC Stakeholders meeting Report 13JUNE2021
- SAVAC Stakeholders meeting Report
13JUNE2021.pdf Download
SAVAC High Level Development Strategy 8MAY2020
- SAVAC High Level Development Strategy
8MAY2020.pdf Download
Vekemans WHO GAS vaccine R&D roadmap CID 2019
- Vekemans WHO GAS vaccine R&D roadmap CID
2019.pdf Download
WHO-IVB-18.07-WHO Preferred Product Characteristics for
GAS Vaccines 2018
- WHO-IVB-18.07-WHO Preferred Product
Characteristics for GAS Vaccines 2018.pdf Download
WHO-IVB-18.08-GAS Vaccine Develoment Technology Roadmap
2018
- WHO-IVB-18.08-GAS Vaccine Develoment
Technology Roadmap 2018.pdf Download